The US FDA approval of Erbitux® (Cetuximab) (an IgG1 monoclonal antibody, for use in the treatment of squamous cell carcinoma of the head and neck) was recently announced by ImClone Systems Incorporated and Bristol-Myers Squibb Company.
The first and only monoclonal antibody to be approved for the treatment of head and neck cancer, Erbitux® is designed to inhibit the function of the epidermal growth factor receptor (EGFR), a molecular structure linked to the tumor growth.
Erbitux® will now be indicated for use in combination with radiation therapy for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and as a single agent in recurrent or metastatic SCCHN where prior platinum-based chemotherapy has failed.
Read more at Bristol-Myers Squibb Newsroom.
.jpg)
Comment Preview